Ketorolac on Posterior Thoracolumbar Spinal Fusions
Launched by HENRY FORD HEALTH SYSTEM · Sep 8, 2017
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called ketorolac, which is a type of pain reliever, in patients who are undergoing a specific type of back surgery known as thoracolumbar spinal fusion. The goal is to find out if taking a low dose of ketorolac within the first 48 hours after surgery can help control pain effectively without negatively affecting the healing process of the spine. Researchers want to compare the results of patients who take ketorolac to those who receive other pain relief methods that do not include this medication.
To be eligible for this study, participants must be at least 18 years old and scheduled for elective thoracolumbar spine surgery using minimally invasive techniques. They should not have a recent history of tobacco use, certain medical conditions, or previous surgeries on the same area of the spine. If someone decides to join the trial, they can expect close monitoring by the medical team to ensure their safety and to assess how well the pain relief works. Overall, this study aims to improve pain management strategies for patients recovering from spinal surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years of age
- • Elective thoracolumbar posterior lumbar instrumented interbody fusion
- • Minimally invasive spine surgery (MIS)
- • 3 or fewer levels
- • Bone Morphogenetic Protein (BMP) use in interbody fusion (1.05mg/level or less)
- • Consent to study participation
- Exclusion Criteria:
- • Active tobacco smoker or history of tobacco smoking in the past 6 weeks
- • Previous history of surgery at operative level(s)
- • History of chronic inflammatory/rheumatological condition
- • History of systemic steroid use in the past 3 months
- • Auto/Workers' compensation patients
- • Traumatic pathology at the operative levels
- • Infection at the operative levels
- • Tumor at the operative levels
- • Major psychiatric illness as diagnosed by psychiatrists and on major anti- psychotic/depressants
- • Patients on chemotherapeutic agents in the last 6 months
- • Patients who has a history of allergy to Ketorolac
- • Patients with a history of chemical addiction requiring professional rehabilitation and/or assistance
- • Patients with current creatinine \> 1.5mg/dl
- • Patients with history of coagulopathy
- • Patients with history of hepatic impairment
- • Patients with uncontrolled cardiovascular disease
About Henry Ford Health System
Henry Ford Health System is a comprehensive, nonprofit healthcare organization based in Detroit, Michigan, renowned for its commitment to advancing medical research and patient care. With a robust network of hospitals, outpatient facilities, and specialty clinics, Henry Ford Health System is dedicated to innovation in clinical trials, focusing on translating scientific discoveries into effective treatments. The organization emphasizes multidisciplinary collaboration, leveraging its extensive resources and expertise to address diverse health challenges. Through its clinical research initiatives, Henry Ford Health System aims to enhance patient outcomes and contribute to the advancement of medical knowledge on both a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southfield, Michigan, United States
Patients applied
Trial Officials
Doris Tong, MD
Study Director
Michigan Spine and Brain Surgeons
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials